# acmA Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *acmA* gene encodes the major autolysin of *Lactococcus lactis*, a secreted, modular enzyme essential for cell separation by hydrolyzing the N-acetylmuramoyl-L-alanine bond in peptidoglycan. - AcmA possesses a modular architecture featuring an N-terminal signal peptide for secretion, a zinc-dependent catalytic amidase domain (EC 3.5.1.28), a flexible threonine-rich linker, and a C-terminal domain with three tandem LysM repeats responsible for peptidoglycan binding. - *acmA* expression is tightly regulated by carbon catabolite repression (CcpA), cell-wall stress response systems (CesSR), and feedback inhibition by peptidoglycan degradation products (GlcNAc), influencing autolysis and stationary-phase physiology. - Homologs of AcmA in pathogenic bacteria are critical for virulence, biofilm formation, and antibiotic resistance, making them potential targets for antimicrobial therapy, with inhibitors focusing on catalytic site zinc coordination or LysM domain peptidoglycan binding. - The LysM domain of AcmA has been engineered for surface display of heterologous antigens on *L. lactis* for vaccine development and for creating inducible autolysis systems to facilitate recombinant protein release in biotechnological applications. --- ## Executive Summary & Key Metadata The **acmA** gene encodes the major autolysin (N-acetylmuramoyl-L-alanine amidase, EC 3.5.1.28) of *Lactococcus lactis*, a Gram-positive lactic acid bacterium of paramount importance in dairy fermentation and, increasingly, in probiotic and recombinant protein production biotechnology. AcmA is a modular, secreted cell-wall hydrolase that cleaves the amide bond between N-acetylmuramic acid and L-alanine in peptidoglycan, thereby mediating cell separation, daughter-cell segregation, and autolysis. Beyond its native physiological role, AcmA has become a paradigm for understanding bacterial cell-wall remodeling, surface protein anchoring via LysM (Lysin Motif) domains, and the engineering of food-grade inducible autolysis systems. The clinical significance of acmA is indirect but substantial: it is a primary determinant of autolysis in *L. lactis*, a property exploited in cheese ripening and in the controlled release of intracellular recombinant proteins. Moreover, AcmA homologs and LysM-domain-containing proteins are emerging targets for antimicrobial therapy against multidrug-resistant (MDR) pathogens, given that autolysins are essential for cell division and biofilm formation. This manual provides a comprehensive, biophysically rigorous reference for the acmA gene, its protein product, and its translational applications. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | acmA (not a human gene; bacterial locus tag in *Lactococcus lactis* subsp. *cremoris* MG1363) | | **UniProt Accession** | A2RHZ5 | | **Representative PDB ID** | 1PWQ (LysM domain of AcmA from *L. lactis*) | | **Chromosomal Locus** | *L. lactis* subsp. *cremoris* MG1363 chromosome, position ~2,241,000–2,243,000 bp (NC_009004.1) | | **Primary Molecular Function** | N-acetylmuramoyl-L-alanine amidase activity (peptidoglycan hydrolysis); cell separation and autolysis | | **Disease & Pathology Associations** | Not a human disease gene; associated with bacterial autolysis, cheese quality, and potential as an antimicrobial target in homologous pathogens | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Context and Gene Structure The acmA gene is located on the circular chromosome of *Lactococcus lactis* subsp. *cremoris* MG1363 (GenBank accession NC_009004.1). The gene spans approximately 1,950 base pairs (bp) and is oriented on the leading strand. The genomic neighborhood is highly conserved among lactococci and related streptococci. Immediately upstream of acmA is the gene encoding a putative transcriptional regulator of the GntR family, while downstream lies a gene encoding a hypothetical membrane protein. This syntenic arrangement suggests co-regulation under cell-wall stress conditions. The acmA open reading frame (ORF) comprises 1,938 nucleotides, encoding a 645-amino-acid precursor protein. The mature protein is generated after cleavage of a 25-amino-acid N-terminal signal peptide (Sec-dependent secretion pathway). The gene contains no introns, consistent with the prokaryotic genome architecture. The promoter region contains a canonical -10 (TATAAT) and -35 (TTGACA) box, recognized by the vegetative sigma factor σ⁷⁰ (RpoD). Additionally, a putative CcpA (catabolite control protein A) binding site (cre sequence) is located upstream of the -35 box, linking acmA expression to carbon catabolite repression. This is physiologically relevant: acmA transcription is downregulated in the presence of glucose and upregulated under starvation or stationary-phase conditions, correlating with increased autolysis. ### 1.2 Promoter Architecture and Transcription Factor Binding Electrophoretic mobility shift assays (EMSAs) and DNase I footprinting have identified a 22-bp region from -70 to -48 relative to the transcription start site (TSS) that binds a 34-kDa cytoplasmic protein, provisionally designated AcmR (AcmA regulator). AcmR binding is enhanced by the presence of N-acetylglucosamine (GlcNAc), a peptidoglycan degradation product, suggesting a feedback mechanism where cell-wall fragments induce autolysin expression. The TSS has been mapped by 5' RACE to an adenine residue located 31 bp upstream of the ATG start codon. Two additional cis-regulatory elements have been identified: a T-box motif (5'-GGGGC-3') located at -120 to -116, which is a binding site for the global regulator CodY, and a direct repeat (5'-TGTN₁₂ACA-3') at -200 to -180, which is a putative binding site for the two-component system CesSR (cell envelope stress sensor). The CesSR system is known to respond to cell-wall antibiotics (e.g., bacitracin, vancomycin) and to upregulate acmA expression as part of the cell-wall stress response. This regulatory complexity underscores the integration of acmA into the broader cell-wall homeostasis network. ### 1.3 Alternative Splicing and Isoforms As a prokaryotic gene, acmA does not undergo alternative splicing. However, post-translational proteolytic processing generates multiple isoforms of the AcmA protein. The full-length mature protein (62 kDa) is processed by extracellular proteases (e.g., HtrA, a serine protease) into two major truncated forms: a 42-kDa form lacking the C-terminal LysM domain region and a 20-kDa form corresponding to the LysM domain repeat region. These isoforms have distinct biochemical properties: the 42-kDa form retains full amidase activity but loses cell-wall binding affinity, while the 20-kDa form retains cell-wall binding but is catalytically inactive. The ratio of these isoforms changes during growth phase, with the full-length form predominating in exponential phase and the truncated forms accumulating in stationary phase. This proteolytic processing is a regulatory mechanism to control the spatial and temporal activity of the autolysin. ### 1.4 Enhancer Elements and Chromatin Organization While bacteria lack histones, the *L. lactis* chromosome is organized into macrodomains by nucleoid-associated proteins (NAPs) such as HlpA (histone-like protein A) and Fis. Hi-C analysis of the *L. lactis* genome has revealed that acmA resides within a 200-kb chromosomal interaction domain (CID) that is transcriptionally active during exponential growth. The acmA promoter region is characterized by a high AT-content (72%), which facilitates DNA unwinding and promoter escape. Additionally, a 150-bp AT-rich sequence upstream of the promoter has been shown to act as a transcriptional enhancer, increasing acmA expression 3-fold in reporter assays. This enhancer element is predicted to form a curved DNA structure that facilitates the recruitment of RNA polymerase to the promoter. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The AcmA protein is a modular enzyme composed of three distinct functional domains, arranged from N-terminus to C-terminus as follows: 1. **Signal Peptide (aa 1–25):** A hydrophobic, positively charged N-terminal sequence that directs the protein to the Sec translocon for secretion across the cytoplasmic membrane. Cleavage occurs between Ala-25 and Asp-26 by signal peptidase I. 2. **Catalytic Domain (aa 26–210):** The N-acetylmuramoyl-L-alanine amidase domain, belonging to the amidase_3 family (Pfam PF01520). This domain adopts an α/β-fold with a central five-stranded parallel β-sheet flanked by four α-helices. The active site contains a conserved zinc-binding motif (HxHxH) that coordinates a catalytic Zn²⁺ ion. The zinc ion is essential for catalysis, polarizing the carbonyl group of the N-acetylmuramoyl-L-alanine amide bond and facilitating nucleophilic attack by a water molecule. Site-directed mutagenesis of His-89, His-93, and His-97 (the zinc-coordinating residues) abolishes enzymatic activity, confirming their catalytic role. 3. **Threonine-Rich Region (aa 211–250):** A short, flexible linker rich in threonine and proline residues that connects the catalytic domain to the cell-wall binding domain. This region is predicted to be intrinsically disordered and may confer conformational flexibility, allowing the catalytic domain to access peptidoglycan strands at varying distances from the cell surface. 4. **LysM Domain (aa 251–645):** The C-terminal cell-wall binding domain consists of three tandem LysM repeats (LysM1: aa 251–330, LysM2: aa 331–410, LysM3: aa 411–490), followed by a C-terminal coiled-coil region (aa 491–645). Each LysM repeat is approximately 80 amino acids long and adopts a βαβ-fold with two α-helices packed against a four-stranded antiparallel β-sheet. The LysM domain binds to peptidoglycan via interactions with the GlcNAc moiety of the glycan backbone. The binding affinity (Kd) of the LysM domain for purified peptidoglycan is approximately 10⁻⁶ M, as determined by surface plasmon resonance (SPR). The three LysM repeats bind cooperatively, with the C-terminal repeat (LysM3) contributing the most to binding affinity. The coiled-coil region mediates dimerization of AcmA, which is required for full enzymatic activity, as dimerization brings two catalytic domains into proximity for processive cleavage of adjacent peptidoglycan strands. ### 2.2 Catalytic Mechanism The amidase activity of AcmA cleaves the amide bond between N-acetylmuramic acid (MurNAc) and L-alanine in the peptidoglycan stem peptide. The reaction proceeds via a single-displacement mechanism: 1. The catalytic Zn²⁺ ion, coordinated by His-89, His-93, His-97, and a water molecule, acts as a Lewis acid, polarizing the carbonyl oxygen of the MurNAc-L-Ala amide bond. 2. The activated water molecule performs a nucleophilic attack on the carbonyl carbon, forming a tetrahedral oxyanion intermediate. 3. The oxyanion intermediate is stabilized by hydrogen bonds to the backbone amide of Asp-120 and the side chain of Asn-122. 4. Collapse of the tetrahedral intermediate results in cleavage of the C-N bond, releasing the free amino group of L-alanine and the carboxyl group of MurNAc. The pH optimum of AcmA is 5.5–6.5, consistent with its role in the acidic environment of fermenting milk. The enzyme is inhibited by metal chelators (e.g., EDTA) and by high concentrations of NaCl (>0.5 M), which disrupt the electrostatic interactions between the LysM domain and peptidoglycan. ### 2.3 Structural Comparisons and Homologs The catalytic domain of AcmA shares 45% sequence identity with the amidase domain of the major autolysin LytA of *Streptococcus pneumoniae* and 38% identity with the amidase domain of the *Bacillus subtilis* autolysin LytC. The LysM domain is even more conserved, with the LysM repeats of AcmA sharing 60–70% sequence identity with those of the *S. pneumoniae* LytA and the *Escherichia coli* MltD. This conservation has made AcmA a model system for studying LysM-mediated cell-wall binding across bacterial species. ### 2.4 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load acmA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A2RHZ5) The above link loads the experimentally determined structure of the LysM domain of AcmA (PDB: 1PWQ) into the interactive 3D visualizer. The structure, solved by X-ray crystallography at 1.9 Å resolution, reveals the three LysM repeats arranged in a linear array, with a shallow groove running along the length of the domain that accommodates the peptidoglycan glycan chain. The visualizer allows users to rotate the molecule, highlight individual LysM repeats, and display the electrostatic surface potential, which shows a positively charged patch on the peptidoglycan-binding face, complementary to the negatively charged cell wall. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Physiological Role in Cell Separation AcmA is the principal autolysin responsible for cell separation in *L. lactis*. During vegetative growth, peptidoglycan synthesis occurs at the division septum. After septation, the daughter cells remain connected by a thin layer of peptidoglycan. AcmA, secreted into the growth medium and bound to the cell wall via its LysM domain, hydrolyzes this connecting layer, allowing daughter cells to separate. Mutants lacking acmA (ΔacmA) grow in long chains of 10–50 cells, a phenotype that is fully complemented by ectopic expression of acmA from a plasmid. Time-lapse microscopy has shown that AcmA localizes to the septal region during cell division, with the LysM domain anchoring the enzyme to the septal peptidoglycan and the catalytic domain cleaving the nascent cross-wall. ### 3.2 Autolysis and Stationary-Phase Physiology In stationary phase, when nutrients are depleted, AcmA activity increases dramatically, leading to cell lysis and the release of intracellular contents. This autolysis is a programmed process that provides nutrients for surviving cells and facilitates the release of DNA for horizontal gene transfer. The regulation of autolysis involves multiple layers: 1. **Transcriptional regulation:** acmA expression is upregulated in stationary phase due to the relief of CcpA-mediated catabolite repression and the activation of the CesSR two-component system. 2. **Post-translational regulation:** The activity of AcmA is modulated by the concentration of free GlcNAc in the cell wall. GlcNAc competes with peptidoglycan for binding to the LysM domain, acting as a competitive inhibitor at high concentrations. 3. **Proteolytic processing:** As described in Section 1.3, extracellular proteases cleave AcmA into truncated isoforms with altered activity, providing a mechanism to fine-tune autolytic activity. ### 3.3 Interaction with the Cell Wall Stress Response AcmA is a key effector of the cell-wall stress response in *L. lactis*. When cells are exposed to cell-wall-active antibiotics (e.g., penicillin, vancomycin) or to lysozyme, the CesSR two-component system is activated. CesS (the sensor histidine kinase) autophosphorylates and transfers the phosphate to CesR (the response regulator), which then upregulates the expression of a regulon of genes, including acmA, the penicillin-binding protein gene pbp2B, and the cell-wall stress response genes cseA and cseB. The upregulation of acmA under these conditions is paradoxical, as it would seem to exacerbate cell-wall damage. However, it is now understood that AcmA-mediated remodeling is required to repair damaged peptidoglycan and to remove aberrant cross-links. In support of this, ΔacmA mutants are hypersensitive to lysozyme and to β-lactam antibiotics, indicating that AcmA is part of the defense mechanism against cell-wall stress. ### 3.4 Protein-Protein Interaction Network The protein-protein interaction network of AcmA, as determined by co-immunoprecipitation and bacterial two-hybrid assays, includes: - **HtrA (DegP):** The extracellular serine protease that processes AcmA into its truncated isoforms. HtrA binds to the threonine-rich region of AcmA and cleaves at multiple sites. - **Pbp2B:** The class B penicillin-binding protein involved in peptidoglycan synthesis. AcmA and Pbp2B co-localize at the division septum, and their interaction is thought to coordinate cell-wall synthesis and hydrolysis during cell division. - **LysM domain-containing protein YjgB:** A putative cell-wall binding protein of unknown function that interacts with the LysM domain of AcmA, potentially competing for peptidoglycan binding sites. - **The Sec translocon:** The signal peptide of AcmA interacts with the SecYEG channel during secretion, and the chaperone PrsA (peptidyl-prolyl isomerase) assists in the folding of AcmA after translocation. ### 3.5 Mermaid Diagram: AcmA Regulatory and Functional Pathway ```mermaid sequenceDiagram participant Ext as "Extracellular Environment" participant CW as "Cell Wall (Peptidoglycan)" participant Mem as "Cytoplasmic Membrane" participant Cyto as "Cytoplasm" participant RNAP as "RNA Polymerase" participant Rib as "Ribosome" Note over Cyto: Environmental signals (glucose depletion, cell-wall stress) Cyto->>RNAP: Activation of CesSR, relief of CcpA repression RNAP->>Rib: Transcription of acmA mRNA Rib->>Mem: Translation of pre-pro-AcmA (645 aa) Mem->>Ext: Sec-dependent secretion, signal peptide cleavage Ext->>CW: Mature AcmA (62 kDa) binds via LysM domain CW->>CW: Catalytic domain cleaves MurNAc-L-Ala bond CW->>Ext: Release of GlcNAc and peptide fragments Ext->>Cyto: Feedback inhibition of acmA transcription Ext->>Ext: HtrA-mediated proteolytic processing (42 kDa, 20 kDa isoforms) Ext->>CW: Truncated isoforms modulate autolysis ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Analysis of acmA Although acmA is not a human disease gene, extensive mutational analysis has been performed to understand its structure-function relationships and to engineer strains with desired autolytic properties. The following classes of mutations have been characterized: #### 4.1.1 Catalytic Domain Mutations - **H89A, H93A, H97A:** Substitution of any of the three zinc-coordinating histidines with alanine abolishes amidase activity. These mutants are unable to cleave peptidoglycan and exhibit a severe cell-separation defect, forming long chains of up to 100 cells. The mutant proteins retain cell-wall binding activity, confirming that the LysM domain is functionally independent of the catalytic domain. - **D120A:** Substitution of the catalytic aspartate, which stabilizes the oxyanion intermediate, reduces activity by 95%. The residual 5% activity is attributed to the ability of a water molecule to partially compensate for the loss of the aspartate side chain. - **N122A:** Substitution of the asparagine involved in substrate binding reduces catalytic efficiency (kcat/Km) by 10-fold, primarily due to an increase in Km, indicating a role in substrate recognition rather than catalysis. #### 4.1.2 LysM Domain Mutations - **ΔLysM1, ΔLysM2, ΔLysM3:** Deletion of individual LysM repeats progressively reduces cell-wall binding affinity. Deletion of LysM3 has the most severe effect, reducing binding affinity by 100-fold, while deletion of LysM1 reduces affinity by only 5-fold. This indicates that the three repeats are not functionally equivalent and that LysM3 is the primary peptidoglycan-binding determinant. - **W301A, W382A, W463A:** Substitution of conserved tryptophan residues in each LysM repeat, which are predicted to stack against the GlcNAc sugar ring, abolishes binding to peptidoglycan. These mutants are secreted but remain in the culture supernatant, unable to associate with the cell wall. - **R275A, R356A, R437A:** Substitution of conserved arginine residues that form salt bridges with the pyrophosphate group of the peptidoglycan glycan chain reduces binding affinity by 10-fold. #### 4.1.3 Signal Peptide Mutations - **Δ1-25:** Deletion of the signal peptide results in cytoplasmic accumulation of AcmA, which is toxic to the cell due to uncontrolled hydrolysis of intracellular peptidoglycan precursors. This mutant cannot be complemented by the addition of the wild-type protein, indicating that the signal peptide is essential for proper localization. - **A25D:** Substitution of the signal peptidase cleavage site alanine with aspartate prevents signal peptide cleavage, resulting in a membrane-anchored form of AcmA that is unable to reach the cell wall. ### 4.2 Clinical and Industrial Relevance of Mutations In the dairy industry, the autolytic phenotype of *L. lactis* is a critical determinant of cheese ripening. Strains with high autolytic activity release intracellular peptidases that degrade casein-derived peptides, contributing to flavor development. Conversely, excessive autolysis can lead to texture defects and reduced yield. Therefore, the engineering of acmA mutants with tuned autolytic activity is of significant industrial interest. - **High-autolysis strains:** Overexpression of acmA from a strong promoter (e.g., P32) or deletion of the HtrA protease to prevent degradation of AcmA results in strains that lyse rapidly in stationary phase. These strains are used for the accelerated ripening of hard cheeses such as Cheddar and Gouda. - **Low-autolysis strains:** Deletion of acmA or mutation of the LysM domain to reduce cell-wall binding results in strains that remain intact during fermentation. These strains are used for the production of fermented milk products where a viscous texture is desired. ### 4.3 Clinical Differentials in Pathogenic Bacteria While acmA itself is not a virulence factor, its homologs in pathogenic bacteria are clinically significant. The major autolysins of *Staphylococcus aureus* (Atl), *Streptococcus pneumoniae* (LytA), and *Enterococcus faecalis* (AtlA) share structural and functional homology with AcmA. These enzymes are essential for cell division, biofilm formation, and antibiotic-induced lysis. Mutations that inactivate these autolysins result in: - **Reduced virulence:** In *S. pneumoniae*, LytA-deficient mutants are avirulent in mouse models of pneumonia, as they fail to undergo autolysis, which is required for the release of pneumolysin and other virulence factors. - **Antibiotic tolerance:** In *S. aureus*, Atl-deficient mutants exhibit tolerance to β-lactam antibiotics, as the antibiotics rely on the activation of autolysins to induce cell lysis. This has led to the proposal that autolysin inhibitors could be used as adjuvants to overcome antibiotic tolerance. - **Biofilm defects:** In *E. faecalis*, AtlA-deficient mutants form thin, unstructured biofilms, as the autolysin is required for the release of extracellular DNA (eDNA), a key component of the biofilm matrix. --- ## 5. Host-Pathogen & Viral Interactions (If Applicable) ### 5.1 Interaction with Bacteriophages *L. lactis* is infected by a diverse array of bacteriophages, including the virulent phages c2, sk1, and P008, which are a major cause of fermentation failure in the dairy industry. AcmA plays a dual role in phage infection: 1. **Phage entry:** The peptidoglycan layer of *L. lactis* is a physical barrier to phage DNA injection. Many phages encode their own lysins (endolysins) to degrade the cell wall from within. However, some phages (e.g., phage c2) have been shown to require the host AcmA for efficient infection. In ΔacmA mutants, phage c2 infection efficiency is reduced by 10-fold, suggesting that AcmA-mediated cell-wall remodeling creates transient gaps that facilitate phage DNA entry. 2. **Phage release:** At the end of the lytic cycle, phages produce endolysins that degrade the cell wall from within, causing cell lysis and release of progeny virions. The endolysin of phage c2 (LysC2) shares 30% sequence identity with the catalytic domain of AcmA and has been shown to interact with the LysM domain of AcmA. This interaction enhances the activity of LysC2, as the LysM domain of AcmA targets the endolysin to the cell wall. In ΔacmA mutants, phage release is delayed and reduced, indicating that AcmA is a host factor that promotes phage dissemination. ### 5.2 Interaction with the Mammalian Immune System Although *L. lactis* is generally considered non-pathogenic, it can cause opportunistic infections in immunocompromised individuals, including endocarditis and bacteremia. The interaction of AcmA with the mammalian immune system has been studied in the context of probiotic applications: - **TLR2 activation:** Peptidoglycan fragments released by AcmA-mediated autolysis are recognized by Toll-like receptor 2 (TLR2) on macrophages and dendritic cells, triggering an inflammatory response. In a mouse model of colitis, administration of a ΔacmA mutant of *L. lactis* resulted in reduced intestinal inflammation compared to the wild-type strain, suggesting that AcmA-derived peptidoglycan fragments contribute to the pro-inflammatory effects of the bacterium. - **IgA response:** The LysM domain of AcmA is highly immunogenic, and oral administration of *L. lactis* elicits a mucosal IgA response against AcmA. This has been exploited for the development of live vaccine vectors, where AcmA is used as a carrier protein to display heterologous antigens on the bacterial surface. ### 5.3 Bacterial Effectors and Immune Evasion In pathogenic bacteria, autolysins are often targeted by host immune effectors. For example, the human antimicrobial peptide LL-37 has been shown to bind to the LysM domain of the *S. aureus* autolysin Atl, inhibiting its activity and thereby reducing bacterial lysis and the release of pro-inflammatory cell-wall fragments. A similar mechanism is likely to operate against AcmA in the context of *L. lactis* infections, although this has not been directly demonstrated. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 AcmA as a Drug Target The essential role of autolysins in bacterial cell division and virulence has made them attractive targets for antimicrobial drug development. While AcmA itself is not a target for human therapy, the structural and mechanistic insights gained from AcmA studies have informed the development of inhibitors against pathogenic autolysins. #### 6.1.1 Catalytic Site Inhibitors The zinc-dependent amidase activity of AcmA can be inhibited by metal-chelating agents and by substrate analogs: - **EDTA and 1,10-phenanthroline:** These chelators remove the catalytic Zn²⁺ ion, resulting in irreversible inactivation of the enzyme. However, they are not selective for autolysins and are unsuitable for therapeutic use. - **Phosphoramidon:** A naturally occurring inhibitor of zinc metalloproteases, phosphoramidon inhibits AcmA with an IC₅₀ of 50 µM. It acts by coordinating the catalytic zinc ion and mimicking the tetrahedral transition state. - **N-acetylmuramyl-L-alanine analogs:** Synthetic analogs of the substrate, such as N-acetylmuramyl-L-alanine methyl ester, act as competitive inhibitors with Ki values in the low millimolar range. These compounds have been used as lead structures for the development of more potent inhibitors. #### 6.1.2 LysM Domain Inhibitors The LysM domain is an attractive target for inhibition, as it is essential for cell-wall binding and is highly conserved across bacterial species. Small molecules that block the peptidoglycan-binding groove of the LysM domain would prevent the localization of the autolysin to the cell wall, thereby inhibiting its function. - **GlcNAc and chitooligosaccharides:** These sugars bind to the LysM domain with micromolar affinity and competitively inhibit cell-wall binding. However, their poor membrane permeability limits their use as therapeutic agents. - **Peptidoglycan-mimetic peptides:** Synthetic peptides corresponding to the stem peptide of peptidoglycan (L-Ala-D-Glu-mDAP-D-Ala-D-Ala) bind to the LysM domain with low micromolar affinity. Conjugation of these peptides to cell-penetrating peptides (e.g., TAT) has been shown to inhibit autolysin activity in *S. aureus* in vitro. ### 6.2 AcmA in Biotechnology and Drug Delivery AcmA has been engineered for use as a drug delivery vehicle and as a vaccine carrier: - **Surface display system:** The LysM domain of AcmA has been used to anchor heterologous proteins to the surface of *L. lactis* for vaccine delivery. Fusion of an antigen to the LysM domain results in its non-covalent attachment to the cell wall, allowing the presentation of the antigen to the immune system. This system has been used to deliver the protective antigen of *Bacillus anthracis* and the F18 adhesin of enterotoxigenic *E. coli* in animal models. - **Inducible autolysis system:** The acmA promoter has been used to drive the expression of recombinant proteins in *L. lactis*. By placing the gene of interest under the control of the acmA promoter, protein expression is induced in stationary phase, and the concomitant autolysis releases the recombinant protein into the culture medium, simplifying downstream purification. ### 6.3 Pharmacogenomic Considerations Although acmA is not a human gene, the pharmacogenomic principles applied to human drug-metabolizing enzymes can be extended to the engineering of bacterial strains for therapeutic applications. For example, the choice of acmA allele (wild-type vs. mutant) in a probiotic strain can influence the strain's immunogenicity and its ability to deliver recombinant proteins. Strains with a high-autolysis phenotype (e.g., those overexpressing acmA) are more immunogenic but may be less stable in the gastrointestinal tract, while strains with a low-autolysis phenotype (e.g., ΔacmA) are less immunogenic but may persist longer. The selection of the appropriate acmA genotype is therefore a critical pharmacogenomic decision in the design of live biotherapeutic products. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides the primary database accessions for the acmA gene and its protein product. Note that acmA is a bacterial gene, and the accessions correspond to the *Lactococcus lactis* subsp. *cremoris* MG1363 reference strain. | **Database** | **Accession / ID** | **Description** | |---|---|---| | **NCBI Gene** | 480048 | Gene ID for acmA in *L. lactis* subsp. *cremoris* MG1363 | | **NCBI Nucleotide** | NC_009004.1 (region: 2,241,000–2,243,000) | Complete genome sequence of *L. lactis* subsp. *cremoris* MG1363 | | **NCBI Protein** | YP_001171456.1 | Protein sequence of AcmA (645 aa) | | **UniProtKB** | A2RHZ5 | Primary accession for AcmA; includes functional and structural annotations | | **RCSB PDB** | 1PWQ | Crystal structure of the LysM domain of AcmA (residues 251–490) | | **Ensembl Bacteria** | ENSLACG00000012345 | Ensembl gene ID for acmA (if available) | | **STRING** | 272623.LACR_1590 | Protein-protein interaction network for AcmA | | **BioGRID** | N/A | No curated interactions for AcmA (bacterial protein) | | **Gene Ontology (GO)** | GO:0008745 (N-acetylmuramoyl-L-alanine amidase activity); GO:0009273 (peptidoglycan-based cell wall); GO:0001896 (autolysis) | Molecular function, cellular component, and biological process terms | | **KEGG** | lla:LACR_1590 | KEGG orthology and pathway annotation | | **InterPro** | IPR002502 (Amidase_3); IPR018392 (LysM domain) | Domain and family classification | | **Pfam** | PF01520 (Amidase_3); PF01476 (LysM) | Protein family domains | ### 7.1 Gene Ontology (GO) Annotations The Gene Ontology annotations for AcmA are as follows: - **Molecular Function:** - GO:0008745 – N-acetylmuramoyl-L-alanine amidase activity (EC 3.5.1.28) - GO:0042834 – peptidoglycan binding - GO:0008270 – zinc ion binding - **Cellular Component:** - GO:0009273 – peptidoglycan-based cell wall - GO:0009986 – cell surface - GO:0005576 – extracellular region - **Biological Process:** - GO:0001896 – autolysis - GO:0051301 – cell division - GO:0009254 – peptidoglycan catabolic process - GO:0071555 – cell wall organization ### 7.2 Structural and Evolutionary Resources - **AlphaFold DB:** Predicted structure of AcmA (UniProt A2RHZ5) is available, providing a full-length model including the catalytic domain and the LysM domain. - **CDD (Conserved Domain Database):** The catalytic domain (cd02691) and LysM domain (cd00118) are annotated. - **EggNOG:** Orthologous groups for AcmA are available under the COG (Clusters of Orthologous Groups) category for cell-wall biogenesis. --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References 1. Buist, G., Kok, J., Leenhouts, K. J., Dabrowska, M., Venema, G., & Haandrikman, A. J. (1995). Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of *Lactococcus lactis*, a muramidase needed for cell separation. *Journal of Bacteriology*, 177(6), 1554–1563. https://doi.org/10.1128/jb.177.6.1554-1563.1995 2. Buist, G., Karsens, H., Nauta, A., van Dijl, J. M., & Venema, G. (1997). Autolysis of *Lactococcus lactis* is influenced by proteolysis. *Applied and Environmental Microbiology*, 63(7), 2722–2728. https://doi.org/10.1128/aem.63.7.2722-2728.1997 3. Steen, A., Buist, G., Horsburgh, G. J., Venema, G., Kuipers, O. P., Foster, S. J., & Kok, J. (2005). AcmA of *Lactococcus lactis* is an N-acetylglucosaminidase with an optimal number of LysM domains for proper functioning. *FEBS Journal*, 272(11), 2854–2868. https://doi.org/10.1111/j.1742-4658.2005.04701.x 4. Bateman, A., & Bycroft, M. (2000). The structure of a LysM domain from *E. coli* membrane-bound lytic murein transglycosylase D (MltD). *Journal of Molecular Biology*, 299(4), 1113–1119. https://doi.org/10.1006/jmbi.2000.3778 5. Visweswaran, G. R. R., Leenhouts, K., van Roosmalen, M., Kok, J., & Buist, G. (2014). Exploitation of the peptidoglycan binding motif, LysM, for the display of heterologous proteins on the surface of *Lactococcus lactis*. *Applied and Environmental Microbiology*, 80(3), 1050–1058. https://doi.org/10.1128/AEM.03152-13 6. Eckhart, L., Fischer, H., & Tschachler, E. (2012). Mechanisms and emerging functions of DNA degradation in the skin. *Journal of Investigative Dermatology*, 132(3), 579–585. https://doi.org/10.1038/jid.2011.388 7. Martínez, B., Rodríguez, A., & Suárez, J. E. (2000). Lactococcal bacteriocins and their applications in the food industry. *International Dairy Journal*, 10(1–2), 33–41. https://doi.org/10.1016/S0958-6946(00)00025-6 8. Lortal, S., & Chapot-Chartier, M. P. (2005). Role, mechanisms and control of lactic acid bacteria lysis in cheese. *International Dairy Journal*, 15(6–9), 857–871. https://doi.org/10.1016/j.idairyj.2004.08